title: Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial?
authors.forename: Athol U
authors.initials: AU
authors.lastname: Wells
authors.forename: Panagiota
authors.initials: P
authors.lastname: Latsi
authors.forename: W Joseph
authors.initials: WJ
authors.lastname: McCune
mesh_terms: D003520:Cyclophosphamide / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D018579:Patient Selection; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000209:etiology; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014797:Vital Capacity
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide